370 related articles for article (PubMed ID: 28338377)
1. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
Wang X; Liu J; Drummond CA; Shapiro JI
Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
[TBL] [Abstract][Full Text] [Related]
2. The Redox-Sensitive Na/K-ATPase Signaling in Uremic Cardiomyopathy.
Liu J; Nie Y; Chaudhry M; Bai F; Chuang J; Sodhi K; Shapiro JI
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32069992
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy.
Liu J; Tian J; Chaudhry M; Maxwell K; Yan Y; Wang X; Shah PT; Khawaja AA; Martin R; Robinette TJ; El-Hamdani A; Dodrill MW; Sodhi K; Drummond CA; Haller ST; Kennedy DJ; Abraham NG; Xie Z; Shapiro JI
Sci Rep; 2016 Oct; 6():34592. PubMed ID: 27698370
[TBL] [Abstract][Full Text] [Related]
4. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling.
Kennedy DJ; Malhotra D; Shapiro JI
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):3-14. PubMed ID: 17535729
[TBL] [Abstract][Full Text] [Related]
5. Central Role for Adipocyte Na,K-ATPase Oxidant Amplification Loop in the Pathogenesis of Experimental Uremic Cardiomyopathy.
Sodhi K; Wang X; Chaudhry MA; Lakhani HV; Zehra M; Pratt R; Nawab A; Cottrill CL; Snoad B; Bai F; Denvir J; Liu J; Sanabria JR; Xie Z; Abraham NG; Shapiro JI
J Am Soc Nephrol; 2020 Aug; 31(8):1746-1760. PubMed ID: 32587074
[TBL] [Abstract][Full Text] [Related]
6. Uremic Toxins Activates Na/K-ATPase Oxidant Amplification Loop Causing Phenotypic Changes in Adipocytes in In Vitro Models.
Bartlett DE; Miller RB; Thiesfeldt S; Lakhani HV; Khanal T; D Pratt R; Cottrill CL; Klug RL; Adkins NS; Bown PC; Nease DB; Shapiro JI; Sodhi K
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201874
[TBL] [Abstract][Full Text] [Related]
7. Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress.
Liu J; Lilly MN; Shapiro JI
Curr Pharm Des; 2018; 24(3):359-364. PubMed ID: 29318961
[TBL] [Abstract][Full Text] [Related]
8. Adipocyte Na, K-ATPase Signaling Attenuates Experimental Uremic Cardiomyopathy.
Sodhi K; Wang X; Chaudhary MA; Lakhani HV; Zehra M; Nawab A; Cottrill CL; Bai F; Liu J; Sanabria JR; Xie Z; Shapiro JI
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):197-206. PubMed ID: 37571879
[TBL] [Abstract][Full Text] [Related]
9. The Role of Na/K-ATPase Signaling in Oxidative Stress Related to Obesity and Cardiovascular Disease.
Srikanthan K; Shapiro JI; Sodhi K
Molecules; 2016 Sep; 21(9):. PubMed ID: 27598118
[TBL] [Abstract][Full Text] [Related]
10. Blockage of the Na-K-ATPase signaling-mediated oxidant amplification loop elongates red blood cell half-life and ameliorates uremic anemia induced by 5/6th PNx in C57BL/6 mice.
Liu J; Chaudhry M; Bai F; Chuang J; Chaudhry H; Al-Astal AY; Nie Y; Sollars V; Sodhi K; Seligman P; Shapiro JI
Am J Physiol Renal Physiol; 2022 Jun; 322(6):F655-F666. PubMed ID: 35435001
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic abnormalities and uremic cardiomyopathy.
Stewart GA; Gansevoort RT; Mark PB; Rooney E; McDonagh TA; Dargie HJ; Stuart R; Rodger C; Jardine AG
Kidney Int; 2005 Jan; 67(1):217-26. PubMed ID: 15610245
[TBL] [Abstract][Full Text] [Related]
12. The physiological and clinical importance of sodium potassium ATPase in cardiovascular diseases.
Yan Y; Shapiro JI
Curr Opin Pharmacol; 2016 Apr; 27():43-9. PubMed ID: 26891193
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal transplantation on uremic cardiomyopathy.
Parfrey PS; Harnett JD; Foley RN; Kent GM; Murray DC; Barre PE; Guttmann RD
Transplantation; 1995 Nov; 60(9):908-14. PubMed ID: 7491692
[TBL] [Abstract][Full Text] [Related]
14. The Na/K-ATPase Signaling: From Specific Ligands to General Reactive Oxygen Species.
Pratt RD; Brickman CR; Cottrill CL; Shapiro JI; Liu J
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200500
[TBL] [Abstract][Full Text] [Related]
15. Microvolt T-wave alternans in end-stage renal disease patients--associations with uremic cardiomyopathy.
Patel RK; Mark PB; Halliday C; Steedman T; Dargie HJ; Cobbe SM; Jardine AG
Clin J Am Soc Nephrol; 2011 Mar; 6(3):519-27. PubMed ID: 21088291
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of active sodium and potassium transport in erythrocytes in children with different stages of symptomatic uremia.
Sigström L
Acta Paediatr Scand; 1981; 70(3):361-8. PubMed ID: 6454327
[TBL] [Abstract][Full Text] [Related]
17. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.
Mark PB; Johnston N; Groenning BA; Foster JE; Blyth KG; Martin TN; Steedman T; Dargie HJ; Jardine AG
Kidney Int; 2006 May; 69(10):1839-45. PubMed ID: 16508657
[TBL] [Abstract][Full Text] [Related]
18. Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function.
Periyasamy SM; Chen J; Cooney D; Carter P; Omran E; Tian J; Priyadarshi S; Bagrov A; Fedorova O; Malhotra D; Xie Z; Shapiro JI
Kidney Int; 2001 Dec; 60(6):2367-76. PubMed ID: 11737612
[TBL] [Abstract][Full Text] [Related]
19. [Cardiac manifestations of terminal kidney insufficiency. Current characterization of uremic cardiomyopathy].
Josephs W; Odenthal HJ
Dtsch Med Wochenschr; 1995 Feb; 120(5):141-4. PubMed ID: 7843032
[No Abstract] [Full Text] [Related]
20. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Kovács ZZA; Szűcs G; Freiwan M; Kovács MG; Márványkövi FM; Dinh H; Siska A; Farkas K; Kovács F; Kriston A; Horváth P; Kővári B; Cserni BG; Cserni G; Földesi I; Csont T; Sárközy M
Sci Rep; 2021 Sep; 11(1):17495. PubMed ID: 34471171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
